WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H592453
CAS#: 63302-01-2 (sodium)
Description: Levodopa is the naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE.
Hodoodo Cat#: H592453
Name: Levodopa sodium
CAS#: 63302-01-2 (sodium)
Chemical Formula: C9H10NNaO4
Exact Mass: 197.07
Molecular Weight: 219.172
Elemental Analysis: C, 49.32; H, 4.60; N, 6.39; Na, 10.49; O, 29.20
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 63302-01-2 (sodium) 59-92-7 (free base),
Synonym: Levodopa
IUPAC/Chemical Name: sodium (S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
InChi Key: LRRQZAXMUDRSPC-RGMNGODLSA-M
InChi Code: InChI=1S/C9H11NO4.Na/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5;/h1-2,4,6,11-12H,3,10H2,(H,13,14);/q;+1/p-1/t6-;/m0./s1
SMILES Code: O=C([O-])[C@@H](N)CC1=CC=C(O)C(O)=C1.[Na+]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 219.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Pelicioni PHS, Brodie MA, Latt MD, Menant JC, Menz HB, Fung VSC, Lord SR. Head and trunk stability during gait before and after levodopa intake in Parkinson's disease subtypes. Exp Gerontol. 2018 Jul 3;111:78-85. doi: 10.1016/j.exger.2018.06.031. [Epub ahead of print] PubMed PMID: 30017993.
2: Fahimi Z, Jahromy MH. Effects of blackberry (Morus nigra) fruit juice on levodopa-induced dyskinesia in a mice model of Parkinson's disease. J Exp Pharmacol. 2018 Jul 4;10:29-35. doi: 10.2147/JEP.S161782. eCollection 2018. PubMed PMID: 30013404; PubMed Central PMCID: PMC6037159.
3: Wu N, Wan Y, Song L, Qi C, Liu Z, Gan J. The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats. Neuropsychiatr Dis Treat. 2018 Jul 5;14:1779-1786. doi: 10.2147/NDT.S162562. eCollection 2018. PubMed PMID: 30013350; PubMed Central PMCID: PMC6038854.
4: Mohamed D, Hegazy MA, Elshahed MS, Toubar SS, Helmy MI. Novel contribution to the simultaneous monitoring of pramipexole dihydrochloride monohydrate and levodopa as co-administered drugs in human plasma utilizing UPLC-MS/MS. Eur J Mass Spectrom (Chichester). 2018 Jan 1:1469066718788800. doi: 10.1177/1469066718788800. [Epub ahead of print] PubMed PMID: 30012017.
5: Antonini A, Nitu B. Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease. J Neural Transm (Vienna). 2018 Jul 13. doi: 10.1007/s00702-018-1906-0. [Epub ahead of print] Review. PubMed PMID: 30006821.
6: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK501337/ PubMed PMID: 30000396.
7: Chung JW, Burciu RG, Ofori E, Coombes SA, Christou EA, Okun MS, Hess CW, Vaillancourt DE. Beta-band oscillations in the supplementary motor cortex are modulated by levodopa and associated with functional activity in the basal ganglia. Neuroimage Clin. 2018 May 18;19:559-571. doi: 10.1016/j.nicl.2018.05.021. eCollection 2018. PubMed PMID: 29984164; PubMed Central PMCID: PMC6029579.
8: Picazio S, Ponzo V, Caltagirone C, Brusa L, Koch G. Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias. J Neurol. 2018 Jul 6. doi: 10.1007/s00415-018-8945-1. [Epub ahead of print] PubMed PMID: 29980853.
9: Tran TN, Vo TNN, Frei K, Truong DD. Levodopa-induced dyskinesia: clinical features, incidence, and risk factors. J Neural Transm (Vienna). 2018 Jul 3. doi: 10.1007/s00702-018-1900-6. [Epub ahead of print] Review. PubMed PMID: 29971495.
10: Rojo-Bustamante E, Abellanas MA, Clavero P, Thiolat ML, Li Q, Luquin MR, Bezard E, Aymerich MS. The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia. Neurobiol Dis. 2018 Jun 21;118:64-75. doi: 10.1016/j.nbd.2018.06.019. [Epub ahead of print] PubMed PMID: 29936234.
11: Ryan MB, Bair-Marshall C, Nelson AB. Aberrant Striatal Activity in Parkinsonism and Levodopa-Induced Dyskinesia. Cell Rep. 2018 Jun 19;23(12):3438-3446.e5. doi: 10.1016/j.celrep.2018.05.059. PubMed PMID: 29924988.
12: Fernandez-Pajarin G, Ares-Pensado B, Sesar A, Iglesias-Canle J, Masa-Vazquez L, Castro A. [Outpatient establishment and initial management of treatment with intraduodenal levodopa-carbidopa infusion in advanced Parkinson's disease]. Rev Neurol. 2018 Jul 1;67(1):1-5. Spanish. PubMed PMID: 29923594.
13: Woitalla D, Dunac A, Safavi A, Ceravolo MG, Gomez Esteban JC, Pavese N, Asgharnejad M, Joeres L, Schuller JC, Chaudhuri KR. A noninterventional study evaluating the effectiveness of rotigotine and levodopa combination therapy in younger versus older patients with Parkinson's disease. Expert Opin Pharmacother. 2018 Jun;19(9):937-945. doi: 10.1080/14656566.2018.1480721. Epub 2018 Jun 19. PubMed PMID: 29916262.
14: Cao C, Li D, Zeng K, Zhan S, Huang P, Li X, Sun B. Levodopa Reduces the Phase lag Index of Parkinson's Disease Patients: A Magnetoencephalographic Study. Clin EEG Neurosci. 2018 Jun 1:1550059418781693. doi: 10.1177/1550059418781693. [Epub ahead of print] PubMed PMID: 29914268.
15: Müller T, Möhr JD. Long-term management of Parkinson's disease using levodopa combinations. Expert Opin Pharmacother. 2018 Jun;19(9):1003-1011. doi: 10.1080/14656566.2018.1484108. Epub 2018 Jun 18. PubMed PMID: 29913079.
16: Vizcarra JA, Situ-Kcomt M, Artusi CA, Duker AP, Lopiano L, Okun MS, Espay AJ, Merola A. Subthalamic deep brain stimulation and levodopa in Parkinson's disease: a meta-analysis of combined effects. J Neurol. 2018 Jun 16. doi: 10.1007/s00415-018-8936-2. [Epub ahead of print] Review. PubMed PMID: 29909467.
17: Vo A, Seergobin KN, MacDonald PA. Independent effects of age and levodopa on reversal learning in healthy volunteers. Neurobiol Aging. 2018 May 18;69:129-139. doi: 10.1016/j.neurobiolaging.2018.05.014. [Epub ahead of print] PubMed PMID: 29894903.
18: García Esteban E, Cózar-Bernal MJ, Rabasco Álvarez AM, González-Rodríguez ML. A Comparative Study of Stabilizing Effect and Antioxidant Activity of Different Antioxidants on Levodopa-Loaded Liposomes. J Microencapsul. 2018 Jun 11:1-33. doi: 10.1080/02652048.2018.1487473. [Epub ahead of print] PubMed PMID: 29889613.
19: Senek M, Nyholm D, Nielsen EI. Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson's disease patients. Eur J Clin Pharmacol. 2018 Jun 7. doi: 10.1007/s00228-018-2497-2. [Epub ahead of print] PubMed PMID: 29882153.
20: Pieterman M, Adams S, Jog M. Method of Levodopa Response Calculation Determines Strength of Association With Clinical Factors in Parkinson Disease. Front Neurol. 2018 May 17;9:260. doi: 10.3389/fneur.2018.00260. eCollection 2018. PubMed PMID: 29867708; PubMed Central PMCID: PMC5966537.
